Biotechnology News & Press Release Distribution

Biotechnology

APAC
Global

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives

CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. ("Unison") are pleased to announce a research collaboration on an undisclosed bacterial target. Under the terms of the agreement, Vernalis will use it...

2022-09-05 16:00 2543

Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

ROCKVILLE, Md. and SUZHOU, China, Sept. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2022-09-05 08:00 2439

Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer

- CornerStone-001(NCT05163223), the multiregional clinical trial for breast cancer treatment, received U.S. FDA approval for Phase 2 trial following the approvals inAustralia and the Taiwan region. - As the same patient group and design of a pivotal study are adopted, a placebo-controlled randomi...

2022-09-05 07:00 1874

Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022

* Non-clinical studies explored the potent anti-fibrotic and anti-inflammatory efficacy of BBT-301 and BBT-209 for IPF treatment * Company enhances its strategic focus on fibrotic diseases inclusive of IPF with 1 clinical asset and 2 non-clinical assets BOSTON and SEONGNAM, South Korea ,Sept. ...

2022-09-02 09:41 1615

Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and intriple class refractory R/R MM. * XPOVIO® is the f...

2022-09-01 08:30 2370

Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum

Addition increases diversity of Board governance and supports further independent expertise DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing...

2022-09-01 07:30 2450

Broncus (02216.HK) announced interim results

The operating revenue had a year-on-year increase by 12.8% in 2022, and the loss narrowed by 62.8%, gradually forming a closed-loop model of "diagnosis + treatment+ chronic disease management" for major pulmonary diseases HANGZHOU, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, 2022, Broncus ...

2022-08-31 22:04 4174

Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet pat...

2022-08-31 21:00 2414

Quris Earns Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction

Analysts found that the Quris Bio-AI Clinical Prediction Platform enhances drug development process agility, shortens discovery timelines, increases drug safety, and improves drug pipeline diversification opportunities SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ -- Frost & Sullivan recently research...

2022-08-31 20:00 2461

WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey

CRANBURY, N.J., Aug. 31, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced the release of its GMP phase I drug substance clinical manufacturing facility, MFG18, inCranbury, New Jersey...

2022-08-31 20:00 2110

Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.

Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market SHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, Beijing Minhai Biotechnology Co., Ltd. held a signing ceremony with Phil. Pharmawealth, Inc. for their cooperation in jointly promoting th...

2022-08-31 17:05 1605

TikoMed's ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spec...

2022-08-31 15:29 1475

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update

- Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Mainland China onMay 13, 2022 - Adjusted loss reduced to RMB 126 million for the first six months of 2022 fromRMB 210 million in the same period last year - Cash and bank balances of RMB 2.151 billion...

2022-08-31 08:29 2477

Viva Biotech Announced 2022 Interim Results

Order Backlog Expected to Empower Future Growth with Increasing Long-term Competitive Advantages Financial Highlights for the 6 months ended June 30, 2022: * Revenue amounted to RMB1,108.7 million, representing a year-on-year ("YoY") increase of 8.0% * Gross profit amounted to RMB345.0 milli...

2022-08-29 23:55 3376

Minderoo Foundation and Illumina Commit $40M to Apply Advanced Genomics to Marine Conservation

New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods SAN DIEGO, Aug. 29, 2022 /PRNewswire/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a40 million Au...

2022-08-29 21:26 2965

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 29, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment o...

2022-08-29 21:00 2220

NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER

* H002 is a precision therapeutic candidate for the treatment of NSCLC, with broad spectrum and high selectivity against multiple EGFR mutations including those with EGFR C797S mutation. * RedCloud Bio has initiated H002 Phase I/IIa clinical studies in both China and US. SHANGHAI, Aug. 29, 20...

2022-08-29 19:30 1990

Sanyou Biopharmaceuticals and KangaBio established strategic collaboration to accelerate antibody drug development and innovation

SHANGHAI, Aug. 27, 2022 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals ( Shanghai) Co., Ltd. (Sanyou) and Shanghai KangaBio Co., Ltd. (KangaBio) have reached an antibody drug licensing agreement, regarding a proprietary monoclonal antibody drug developed by Sanyou, which grants KangaBio an e...

2022-08-28 08:00 3985

Ascentage Pharma Announces 2022 Interim Results

SUZHOU, China and ROCKVILLE, Md. , Aug. 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results. During the reporting p...

2022-08-27 00:47 12794

Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead™ RNAi delivery platform f...

2022-08-26 21:54 9678

1 ... 114 115 116117118 119 120 ... 279